Financial Performance - Lexeo Therapeutics reported a net loss of $20.9 million or $0.27 per share for Q4 2025, compared to a net loss of $25.9 million or $0.78 per share for Q4 2024[11] - Total cash, cash equivalents, and investments were $246.6 million as of December 31, 2025, expected to fund operations into 2028[12] - Research and Development expenses decreased to $16.2 million for Q4 2025 from $18.4 million in Q4 2024, and for the full year, they were $63.8 million compared to $74.1 million in 2024[11] - General and Administrative expenses for Q4 2025 were $6.9 million, down from $9.0 million in Q4 2024, while for the full year, they increased to $45.5 million from $31.7 million in 2024[11] Clinical Development - The company initiated the submission of the final registrational trial design and statistical analysis plan for the SUNRISE-FA 2 pivotal study to the FDA in February 2026[3] - Interim clinical data for LX2006 showed improvements in cardiac structure and functional outcomes, including reduced left ventricular mass index (LVMI)[3] - Anticipated milestones for 2026 include FDA feedback on protocol submission expected in Q2 and initiation of the SUNRISE-FA 2 pivotal trial in the first half of 2026[8] Strategic Collaborations and Financing - Lexeo established a research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy[8] - The company executed a $154 million equity financing in October 2025 to advance its cardiac pipeline and support registrational readiness activities for LX2006[8] Leadership Changes - The leadership team was strengthened with the appointment of a new Chief Medical Officer, enhancing expertise in cardiovascular medicine[8]
Lexeo Therapeutics(LXEO) - 2025 Q4 - Annual Results